newsfilter
← Latest News
PR Newswire·

Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

STOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that an abstract about its lead program fos